From a biochemical pharmacy viewpoint, Relafen 750 (naproxen sodium) signifies a compelling case study in noncopyrightal anti-inflammatory agent action. Its mechanism of reducing inflammation and pain copyrights primarily on the inhibition of cyclooxygenase (COX) catalysts, specifically COX-1 and COX-2. Examining the selective nuances of this bindi